Status:
COMPLETED
Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma
Lead Sponsor:
University Hospital Carl Gustav Carus
Conditions:
Multiple Myeloma
Plasmocytoma
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
Patients with stage-I multiple myeloma are treated with a vaccine made from their own immune cells (dendritic cells) and their own myeloma protein. Vaccinations are given on 5 occasions every 4 weeks....
Eligibility Criteria
Inclusion
- multiple myeloma
- stage I (Salmon \& Durie)
- no cytoreductive pre-treatment
Exclusion
- myeloma stages II-III
- asecretory disease
Key Trial Info
Start Date :
March 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2004
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT00988312
Start Date
March 1 2002
End Date
March 1 2004
Last Update
October 2 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Dresden
Dresden, Germany, 01307